Cemsidomide

本期看点 1. 用于治疗阿尔茨海默病的多肽疫苗ACI-35.030的1b/2a期临床试验结果积极，仅需1次注射即可让所有受试者产生抗磷酸化Tau（pTau）IgG抗体滴度，2周时所有剂量组的应答率达100%。 2. 口服小分子IKZF1/3蛋白降解剂cemsidomide联合地塞米松治疗复发/难治性多发性骨髓瘤（RRMM）的1期临床试验数据积极，最高剂量组的总缓解率（ORR）达50%，关键靶蛋白IKZF1的降解率＞50%，IKZF3降解率＞80%。 ACI-35.030（JNJ-2056）：公布1b/2a期临床试验数据 AC Immune公司公布了其用于治疗阿尔茨海默病的免疫疗法ACI-35.030的1b/2a期临床试验结果。ACI-35.030基于AC Immune的SupraAntigen技术平台开发，该技术将pTau肽锚定在脂质体中，同时包含非Tau T细胞表位和佐剂。试验还研究了另一种免疫疗法JACI-35.054，两种疗法针对同一靶点。 临床数据显示，针对同一靶点的两种不同主动免疫疗法制剂，能在早期阿尔茨海默病患者体内诱导产生有差异的抗体反应。安全性方面，ACI-35.030和JACI-35.054均未报告任何具有临床意义的安全性或耐受性问题。ACI-35.030仅需一次注射即可使所有受试者产生抗pTau IgG抗体滴度，并在后续接种中持续提升抗体水平。在接受ACI-35.030治疗后2周时，所有剂量组的所有受试者均被认定为抗pTau IgG应答者。在两个高剂量组中，应答率在第74周时仍维持在94%至100%之间。目前，ACI-35.030已被选中推进至关键性2b期ReTain临床试验，用于治疗临床前期阶段的阿尔茨海默病。 Cemsidomide：公布1期临床试验数据 C4 Therapeutics公司公布了其在研口服小分子IKZF1/3蛋白降解剂cemsidomide联合地塞米松治疗复发/难治性多发性骨髓瘤的1期临床试验数据。截至2025年7月23日的数据，在接受过多线治疗的RRMM患者中，cemsidomide联合地塞米松展现出强劲且持久的抗肿瘤活性。最高剂量组（100 µg）患者的ORR达50%；75 µg剂量组的ORR为40%。所有剂量组的中位缓解持续时间（DOR）为9.3个月，在两个最高剂量组中，中位缓解持续时间尚未达到。 药效学（PD）结果显示，cemsidomide与地塞米松联用可高效降解靶蛋白并激活T细胞，在人外周血单核细胞中，IKZF1的降解率＞50%、IKZF3降解率＞80%，且在所有剂量下均显著增强T细胞活化和IL-2等细胞因子的产生，展现出与地塞米松联用或与地塞米松+BCMA双特异性T细胞衔接器（BCMA BiTE）联用的潜力。安全性方面，没有与cemsidomide相关的停药事件，且很少有剂量减少事件（6%），为其在联合治疗方案中的广泛应用提供了有力支持。 SYT-510：公布1期临床试验数据 Synendos Therapeutics公司公布了其核心候选药物SYT-510在健康受试者中开展的1期临床试验的积极结果。SYT-510靶向内源性大麻素系统（ECS）中一个新近发现的靶点，属于新型ECS调节剂——选择性内源性大麻素再摄取抑制剂（SERIs）类别。 研究结果表明，SYT-510在所有剂量下均具有良好的耐受性，安全性良好。药代动力学（PK）数据显示，SYT-510能够穿透血脑屏障，在中枢神经系统（CNS）中达到有效浓度。该药物展现出明确的脑部药效学作用，其对脑电图（EEG）的影响与成功用于控制焦虑症状的抗焦虑药物一致。 MF-300：公布1期临床试验数据 Epirium Bio公司宣布，其潜在“first-in-class”的口服15-羟基前列腺素脱氢酶（15-PGDH）抑制剂MF-300，在针对肌肉减少症的1期临床试验中取得积极结果。5-PGDH是一种能将前列腺素E2（PGE2）转化为非活性代谢物的酶。MF-300旨在可逆地结合到15-PGDH的PGE2结合位点上，阻止该酶转化PGE2。在生化试验中，MF-300能够抑制15-PGDH的活性。在临床前的细胞和动物研究中，MF-300可稳定和增加PGE2的水平。 此次试验达到了主要安全性终点，所有研究剂量的MF-300总体耐受性良好，且无受试者因不良反应而退出。MF-300呈现出剂量依赖性的PD应答，该应答出现较早并随时间的推移持续存在，而安慰剂组则未观察到显著变化，表明药物成功与靶点结合并具有生物学活性。PK分析显示，药物暴露量随剂量增加而上升，其半衰期支持每日一次口服给药方案。 参考资料： [1] Intellia Therapeutics Announces Positive Longer-Term Phase 1 Data for Nexiguran Ziclumeran (nex-z) in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy. Retrieved September 26, 2025, from https://www.globenewswire.com/news-release/2025/09/25/3156402/0/en/Intellia-Therapeutics-Announces-Positive-Longer-Term-Phase-1-Data-for-Nexiguran-Ziclumeran-nex-z-in-Patients-with-Hereditary-Transthyretin-ATTR-Amyloidosis-with-Polyneuropathy.html [2] Bambusa Therapeutics Announces Highly Positive Healthy Volunteer Results and First Atopic Dermatitis Patient Dosed in Phase I Trial of BBT001. Retrieved September 26, 2025, from https://www.prnewswire.com/news-releases/bambusa-therapeutics-announces-highly-positive-healthy-volunteer-results-and-first-atopic-dermatitis-patient-dosed-in-phase-i-trial-of-bbt001-302567230.html [3] Rallybio Completes Dosing of First Cohort in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study. Retrieved September 26, 2025, from https://www.businesswire.com/news/home/20250924016253/en/Rallybio-Completes-Dosing-of-First-Cohort-in-RLYB116-Phase-1-Confirmatory-PharmacokineticPharmacodynamic-Study [4] uniQure Announces Positive Topline Results from Pivotal Phase I/II Study of AMT-130 in Patients with Huntington’s Disease. Retrieved September 26, 2025, from https://www.globenewswire.com/news-release/2025/09/24/3155348/0/en/uniQure-Announces-Positive-Topline-Results-from-Pivotal-Phase-I-II-Study-of-AMT-130-in-Patients-with-Huntington-s-Disease.html [5] Kyverna Therapeutics Highlights Potential of KYV-101 in Multiple Sclerosis with Data from Phase 1 Investigator-Initiated Trials to be Presented at ECTRIMS. Retrieved September 26, 2025, from https://www.globenewswire.com/news-release/2025/09/24/3155539/0/en/Kyverna-Therapeutics-Highlights-Potential-of-KYV-101-in-Multiple-Sclerosis-with-Data-from-Phase-1-Investigator-Initiated-Trials-to-be-Presented-at-ECTRIMS.html [6] Epirium Bio Announces Positive Phase 1 Clinical Trial Results Evaluating MF-300 in Healthy Volunteers, A First-In-Class, Oral 15-PGDH Enzyme Inhibitor, For the Treatment of Sarcopenia. Retrieved September 26, 2025, from https://www.businesswire.com/news/home/20250924461947/en/Epirium-Bio-Announces-Positive-Phase-1-Clinical-Trial-Results-Evaluating-MF-300-in-Healthy-Volunteers-A-First-In-Class-Oral-15-PGDH-Enzyme-Inhibitor-For-the-Treatment-of-Sarcopenia [7] Actio Biosciences Announces First Participant Dosed in Phase 1 Clinical Trial of ABS-1230, a KCNT1 Inhibitor for the Treatment of KCNT1-Related Epilepsy. Retrieved September 26, 2025, from https://actiobiosciences.com/actio-biosciences-announces-first-participant-dosed-in-phase-1-clinical-trial-of-abs-1230-a-kcnt1-inhibitor-for-the-treatment-of-kcnt1-related-epilepsy/ [8] CellProthera announces peer-reviewed publication of its Phase I/IIb results on safety and feasibility of ProtheraCytes® in patients with severe heart failure post-myocardial Infarction. Retrieved September 26, 2025, from https://www.cellprothera.com/en/cellprothera-announces-peer-reviewed-publication-of-its-phase-i-iib-results-on-safety-and-feasibility-of-protheracytes-in-patients-with-severe-heart-failure-post-myocardial-infarction/ [9] MIRA Pharmaceuticals Announces Favorable Topline Results from Phase 1 SAD Study of Oral Ketamir-2, a Next-Generation Non-Scheduled Ketamine Analog. Retrieved September 26, 2025, from https://mirapharmaceuticals.com/mira-pharmaceuticals-announces-favorable-topline-results-from-phase-1-sad-study-of-oral-ketamir-2-a-next-generation-non-scheduled-ketamine-analog/ [10] Ionis announces positive topline results from pivotal study of zilganersen in Alexander disease. Retrieved September 26, 2025, from https://secure.businesswire.com/news/home/20250922674696/en/Ionis-announces-positive-topline-results-from-pivotal-study-of-zilganersen-in-Alexander-disease [11] Skye Presents Phase 1b Data for its Peripheral CB1-inhibiting Antibody, Nimacimab, at European Association for the Study of Diabetes (EASD) Annual Meeting. Retrieved September 26, 2025, from https://www.globenewswire.com/news-release/2025/09/19/3153078/0/en/Skye-Presents-Phase-1b-Data-for-its-Peripheral-CB1-inhibiting-Antibody-Nimacimab-at-European-Association-for-the-Study-of-Diabetes-EASD-Annual-Meeting.html [12] C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting. Retrieved September 26, 2025, from https://www.globenewswire.com/news-release/2025/09/20/3153507/0/en/C4-Therapeutics-Presents-Cemsidomide-Phase-1-Multiple-Myeloma-Data-Supporting-Potential-Best-in-Class-Profile-at-the-International-Myeloma-Society-Annual-Meeting.html [13] Synendos Therapeutics Reports Positive and Highly Promising Topline Results from Phase 1 Trials, Paving the Way for Phase 2 in Mental Health. Retrieved September 26, 2025, from https://www.globenewswire.com/news-release/2025/09/24/3155178/0/en/Synendos-Therapeutics-Reports-Positive-and-Highly-Promising-Topline-Results-from-Phase-1-Trials-Paving-the-Way-for-Phase-2-in-Mental-Health.html [14] Peer-reviewed results from Phase 1b/2a Trial of Anti-pTau Active Immunotherapy from AC Immune Published in eBioMedicine. Retrieved September 26, 2025, from https://www.globenewswire.com/news-release/2025/09/25/3156158/0/en/Peer-reviewed-results-from-Phase-1b-2a-Trial-of-Anti-pTau-Active-Immunotherapy-from-AC-Immune-Published-in-eBioMedicine.html 免责声明：本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。 版权说明：欢迎个人转发至朋友圈，谢绝媒体或机构未经 授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。 分享，点赞，在看，聚焦全球生物医药健康创新

编者按：诱导接近（induced proximity）机制通过将蛋白或核酸拉近形成复合体，从而调控靶点功能。基于这一机制开发的靶向蛋白降解剂（TPD）已成为新药研发的热点之一。与传统抑制剂不同，它们无需直接抑制靶蛋白活性，而是通过降解疾病相关蛋白，有望靶向许多长期被认为“不可成药”的靶点。药明康德在TPD技术刚刚起步时，就开始布局相关能力和技术，积累了丰富的成功经验，搭建起集发现、合成、分析纯化和测试等能力于一体的一站式赋能平台。目前，该平台已成功支持超过120款TPD分子的开发，其中20余款顺利推进至临床阶段。近年来，基于诱导接近机制的研发已不再局限于TPD，还扩展至针对难以成药靶点的抑制剂开发，以及组织特异性药物的开发。本文将回顾2025年第三季度该领域的最新进展，并介绍药明康德的一体化CRDMO平台如何高效解决诱导接近药物开发过程中的诸多挑战。 靶向蛋白降解：FDA受理PROTAC®疗法新药申请 Arvinas与辉瑞（Pfizer）宣布，美国FDA已受理为PROTAC®疗法vepdegestrant递交的新药申请（NDA），用于治疗既往接受过内分泌治疗、雌激素受体阳性（ER+）/人表皮生长因子受体2阴性（HER2-）且伴有ESR1突变的晚期或转移性乳腺癌患者。根据新闻稿，vepdegestrant是首个在乳腺癌患者中展现临床获益的PROTAC®疗法。若获批，该药物将成为首个获美国FDA批准的PROTAC®雌激素受体降解剂。 除了Arvinas公司，C4 Therapeutics公司还公布了靶向IKZF1/3的在研蛋白降解疗法cemsidomide治疗多发性骨髓瘤患者的1期临床试验结果。截至2025年7月23日，75 µg剂量组的客观缓解率（ORR）为40%，100 µg剂量组的ORR为50%。该公司计划在2026年初启动注册性临床试验。 Monte Rosa Therapeutics公司开发的靶向NEK7的分子胶蛋白降解剂MRT-8102，在1期临床试验中已完成首例患者给药。这款口服选择性分子胶降解剂有望用于治疗与NLRP3、IL-1β和IL-6失调相关的炎症性疾病。值得注意的是，该公司还在《科学》杂志发表论文，详细介绍了其自主开发的人工智能（AI）和机器学习（ML）引擎如何发现可通过CRBN介导降解的人体蛋白，涵盖多种不同的蛋白结构域与类别。这一突破显著拓展了分子胶蛋白降解药物的可操作靶点空间。该公司还在9月15日宣布与诺华（Novartis）达成57亿美元的新研发合作协议，携手推动针对免疫介导疾病的创新降解剂研发。 TPD药物虽具广阔前景，但其开发也面临独特挑战。例如，PROTAC®分子由于分子量大、结构复杂，通常存在溶解度差和药代动力学性质不佳的问题。以下案例展示了药明康德旗下合全药业（WuXi STA）如何与合作伙伴携手，有效应对这些挑战。 解决TPD药物开发痛点，加速创新疗法进入临床试验 几年前，一家公司因PROTAC®分子的生产难题，选择与合全药业合作，希望在14个月内完成候选药物的生产，以支持IND申请及首次人体临床试验。然而，该候选分子的初始合成路线非常复杂，需要多达24个步骤，且最终产率仅为0.3%。此外，PROTAC®特定的分子结构进一步增加了产品结晶和纯化难度。 同时，由于候选化合物分子量较大且水溶性低，其口服生物利用度只有0.9%。值得注意的是，在合成过程中还有三步涉及使用罕见金属钯（Pd）作为催化剂，这不仅带来潜在安全隐患，更显著提高了生产成本。 针对上述问题，合全药业的工艺研发、生物催化及结晶工艺等团队协同攻关，重新设计了一条合成路线，将合成步骤从原来的24步缩减至16步，并在其中两个步骤中用生物催化剂替代了钯催化剂。为攻克结晶难题，团队采用高通量结晶筛选技术，迅速确定了符合纯度与产量要求的结晶工艺，并通过优化大幅提升了生产过程的总产率。这些改进不但极大提高了整体合成工艺的可放大性，也提升了合成效率并降低了成本。 与此同时，合全药业的制剂研发团队针对药物口服生物利用度低的问题，进行了全面的生物利用度增强技术筛选，最终选定喷雾干燥制备固体分散体（SDD）技术进行制剂制备。这种技术将难溶药物以无定形状态高度分散在聚合物中，目前已成功应用于多种上市药物的制剂开发中。借助SDD技术，候选化合物药片制剂的口服生物利用度提高了约30倍，为后续临床应用奠定了坚实基础。 合全药业一体化CRDMO平台的整合能力，使多个团队能够并行推进原料药与制剂开发，高效协作，加速破解PROTAC®分子开发中的难题。最终，团队仅用了12个月就完成了支持IND申请所需的候选药物生产和制剂制备，顺利供应首次人体临床研究用药，比合作伙伴原定时间提前了2个月。 超越蛋白降解：分子胶抑制剂获突破性疗法认定 TPD只是诱导接近机制在新药开发中的一种应用。分子胶通过将靶点蛋白与呈递蛋白（presenter proteins）结合，形成复合表面，从而突破传统药物对活性位点的依赖，让小分子能够靶向更多“不可成药”的靶点，显著拓展了治疗可能性。 例如，Revolution Medicines公司研发的RAS抑制剂elironrasib成功招募了cyclophilin这一呈递蛋白，实现了对激活状态下KRAS G12C蛋白的特异性靶向与抑制。今年7月，该药物获得FDA授予的突破性疗法认定，用于治疗携带KRAS G12C突变的非小细胞肺癌（NSCLC）患者。Elironrasib单药治疗在既往未接受KRAS抑制剂的经治NSCLC患者中达到56%的ORR和94%的疾病控制率（DCR）；与pembrolizumab联用时，一线治疗的ORR更是高达100%，显示出可喜的初步疗效。 Halda Therapeutics公司的调节诱导接近靶向嵌合体（RIPTAC）则代表另一种新策略。这类异双功能分子的一端结合富集于癌细胞中的靶点蛋白，另一端结合细胞生存必需的关键蛋白。当细胞同时表达这两种蛋白时，RIPTAC分子将两者结合形成复合体，使关键蛋白失活，从而诱导癌细胞死亡。 今年8月，Halda Therapeutics宣布与VantAI达成研发合作，利用VantAI的人工智能和结构蛋白组学发现平台，开发治疗癌症和免疫疾病的下一代RIPTAC药物。 越来越多开发诱导接近药物的公司开始利用人工智能技术加速新药发现，除了Halda Therapeutics与VantAI的合作，Revolution Medicines在7月与Iambic Therapeutics也达成研发合作，利用Iambic公司基于AI的蛋白-配体结构预测模型和图像神经网络模型来发现创新候选药物。今年8月，致力于分子胶药物开发的Proxygen宣布与洛桑联邦理工学院（EPFL）建立战略研究合作关系。这一合作旨在将高通量体外筛选与先进计算设计相结合，以系统性地预测和验证新底物-连接酶相互作用，并设计能够诱导靶向蛋白降解的化学分子。 非降解性分子胶的开发也得到投资人的关注。今年9月，Rapafusyn Pharmaceuticals宣布完成4400万美元A轮融资。该公司的RapaGlue平台已展现出生成高协同非降解型分子胶的能力，这些分子胶具有较高的细胞膜通透性，可用于调控蛋白-蛋白相互作用、转录因子、转运蛋白、离子通道、酶等多种难以成药靶点。 一体化平台助力分子胶早期发现 药明康德一体化平台的能力不但涵盖PROTAC®，还包括分子胶、以及多种新兴双功能分子。以分子胶药物发现为例，其早期研发阶段中无偏倚药物筛选的低命中率始终是一大挑战。为助力合作伙伴有效应对这一难题，药明康德采取了“双轨并进”的策略，构建起一套兼顾广度与深度的化合物库体系：一方面，通过多样化的DNA编码化合物库（DEL）大范围探索新靶点；另一方面，借助聚焦化合物库精细化研究已知蛋白体系，提升发现效率。 ▲药明康德分子胶发现平台（图片来源：参考资料[15]） 在分子胶药物的早期发现过程中，药明康德不仅依赖DNA编码化合物库进行筛选，还不断引入并整合多种先进技术，以助力合作伙伴拓展分子胶药物的发现能力。其中，亲和筛选质谱（ASMS）提供无标记筛选手段。药明康德构建了一个涵盖超过37万个小分子的广谱化合物库，通过比较这些分子在单蛋白与双蛋白条件下的质谱信号差异，精准识别出能够促进蛋白–蛋白相互作用的潜在分子胶候选物，从而识别出潜在促互作的小分子。 与此同时，公司还部署高通量筛选（HTS）技术。在“一孔一化合物”的自动化运行模式下，结合蛋白结合能力或降解能力等功能性实验，HTS能迅速锁定具备生物活性的候选分子，大幅提升筛选效率与准确性。通过将ASMS与HTS等多维筛选工具与DEL平台深度融合，药明康德打破了单一筛选方式的限制，让更多不同类型的靶点进入分子胶研究视野，进一步拓宽了分子胶在多类靶点上的研发空间。 展望未来 Broad研究所联合创始人Stuart Schreiber博士在2024年发表的一篇评论文章中指出，基于诱导接近作用的分子胶和双功能化合物为药物发现提供了创新模式。这一模式可以通过新颖的方式调控具有挑战性的靶点，包括稳定、降解、易位、激活，以及重塑转录回路。对于精准医疗而言，这可能提供了一个独特的机会，将“合适的药物在合适的时间、用于合适的患者，在合适的组织中生效”这一理念变为现实。 药明康德将继续秉持“让天下没有难做的药，难治的病”的愿景，依托全球研发基地与生产网络，以独特的一体化、端到端的CRDMO模式，助力包括靶向蛋白降解剂在内的诱导接近药物的开发，帮助合作伙伴将科学创新转化为惠及全球患者的变革性药物。 CRDMO: Q3 2025 Review of Induced Proximity Drugs The induced proximity mechanism regulates target function by bringing proteins or nucleic acids into close proximity to form complexes. Targeted protein degraders (TPDs) developed on this basis have become one of the hottest areas in drug discovery. Unlike traditional inhibitors, TPDs do not need to block target activity directly; instead, they eliminate disease-related proteins, opening opportunities to tackle many proteins once deemed “undruggable.” When TPD technology was still in its infancy, WuXi AppTec started building relevant capabilities. Since then, the company has established a comprehensive, integrated platform encompassing discovery, synthesis, purification, analysis, and testing. To date, this platform has supported the development of more than 120 TPD molecules, with over 20 advancing to clinical stages. In recent years, induced proximity has extended beyond TPDs to include inhibitors for hard-to-drug targets and tissue-specific therapies. This article reviews the latest developments in Q3 2025 and highlights how WuXi AppTec’s integrated CRDMO platform helps overcome the unique challenges of developing induced-proximity medicines. Targeted Protein Degradation: FDA Accepts NDA for a PROTAC® Therapy In a major regulatory milestone, Arvinas and Pfizer announced that the U.S. FDA has accepted the New Drug Application (NDA) for the PROTAC® therapy vepdegestrant. The application covers patients with advanced or metastatic breast cancer who have received prior endocrine therapy and are ER+/HER2− with ESR1 mutations. According to the companies, vepdegestrant is the first PROTAC® therapy to demonstrate clinical benefit in breast cancer. If approved, it will become the first FDA-approved PROTAC® estrogen receptor degrader. Other companies are also making progress. C4 Therapeutics reported Phase 1 clinical results for its protein degrader cemsidomide in multiple myeloma. As of July 23, 2025, the objective response rate (ORR) was 40% in the 75 µg cohort and 50% in the 100 µg cohort. A registrational trial is planned for early 2026. Meanwhile, Monte Rosa Therapeutics announced that the first subjects have been dosed in a Phase 1 study evaluating MRT-8102, a NEK7-directed molecular glue degrader being developed for the treatment of inflammatory conditions driven by the NLRP3 inflammasome, IL-1β, and IL-6. Adding to this progress, Monte Rosa published a paper in Science describing how its proprietary AI and ML engine identified human proteins potentially amenable to CRBN-mediated degradation. The findings, spanning diverse protein domains and classes, significantly broaden the actionable target space for molecular glue degrader discovery. On September 15, the company also announced an agreement to collaborate with Novartis to develop novel degraders for immune-mediated diseases. While clinical advances are encouraging, TPDs still pose unique development hurdles. For example, due to their large molecular weight and structural complexity, PROTAC® compounds often suffer from poor solubility and suboptimal pharmacokinetics. The following case study illustrates how WuXi STA, an integral part of WuXi AppTec, collaborated with a partner to address these challenges effectively. Addressing Key Bottlenecks in TPD Drug Development Several years ago, a biotech company developing a PROTAC® candidate faced synthetic challenges and turned to WuXi STA for support. The goal was to complete the production of drug substance and clinical trial material within 14 months to support an IND filing and FIH trial. However, the original synthesis route involved 24 steps and yielded only 0.3%. Crystallization and purification proved difficult due to the compound’s unique structure. Compounding the challenge, the candidate’s high molecular weight and poor solubility resulted in oral bioavailability of only 0.9%. Moreover, three steps in the synthesis relied on a palladium (Pd) catalyst, raising safety concerns and increasing production costs. To resolve these issues, WuXi STA’s process chemistry, biocatalysis, and crystallization teams worked in concert to redesign the synthesis route, reducing the number of steps from 24 to 16 and replacing palladium with biocatalysts in two steps. To tackle crystallization bottlenecks, high-throughput crystallization screening identified suitable conditions that met both purity and yield requirements. These changes significantly improved the scalability and efficiency of the synthetic route while reducing costs. Simultaneously, WuXi STA’s formulation team addressed the low oral bioavailability by exploring a range of enabling technologies and ultimately selected spray-dried dispersion (SDD) to prepare a solid dosage form. SDD disperses poorly soluble compounds in an amorphous state within a polymer matrix and has been successfully used in several approved drugs. With this approach, the candidate’s oral bioavailability improved by approximately 30-fold—supporting further clinical advancement. Thanks to WuXi STA’s integrated CRDMO model, API process development and formulation were advanced in parallel by multiple teams working seamlessly together. Ultimately, they delivered IND-enabling materials and clinical trial materials within just 12 months—two months ahead of schedule. Beyond Protein Degradation: Molecular Glue Inhibitor Receives Breakthrough Designation Induced proximity is not limited to protein degradation. Molecular glues, which bind a target protein and a presenter protein to form composite binding surfaces, bypass the need to interact with active sites. This allows small molecules to reach a broader range of targets, including those once considered undruggable. A notable example comes from Revolution Medicines. Its RAS inhibitor elironrasib recruited cyclophilin as a presenter protein to selectively target and inhibit active-state KRAS G12C. In July, the FDA granted Breakthrough Therapy Designation for elironrasib in KRAS G12C-mutant NSCLC. Phase 1 data were compelling: in previously treated patients without prior KRAS inhibitors, monotherapy achieved a 56% ORR and 94% disease control rate (DCR). In combination with pembrolizumab as first-line therapy, the ORR reached 100%, signaling strong early potential. Halda Therapeutics is advancing another strategy with Regulated Induced Proximity Targeting Chimeras (RIPTACs). These heterobifunctional molecules bind a cancer-enriched target protein on one end and an essential survival protein on the other. By bringing the two together, RIPTACs inactivate the survival protein, triggering cancer cell death. In August, Halda announced a partnership with VantAI to apply AI and structural proteomics in the discovery of next-generation RIPTACs for cancer and immune diseases. Revolution Medicines also entered a collaboration with Iambic Therapeutics in July, leveraging AI-based protein-ligand prediction and neural network models to accelerate novel candidate discovery. In August, Proxygen announced a strategic research collaboration with EPFL (the Swiss Federal Institute of Technology in Lausanne). The collaboration aims to build a next-generation discovery paradigm that bridges high-throughput in vitro screening with state-of-the-art in silico design. Non-degrading molecular glues also attracted investors’ attention. In September, Rapafusyn Pharmaceuticals announced the closing of its oversubscribed Series A financing round ($44 million). Its RapaGlue platform has demonstrated the ability to create highly cooperative non-degrading molecular glues with high cell membrane permeability to modulate protein–protein interactions, transcription factors, transporters, ion channels, enzymes, and others. WuXi AppTec’s integrated platform supports not only PROTAC® development but also molecular glues and other bifunctional modalities. By uniting cutting-edge screening technologies, tailored library design, and deep scientific expertise, WuXi AppTec offers a fully integrated platform for molecular glue discovery. This approach supports partners across: Hit identification and validation Mechanistic characterization and degradation profiling Lead optimization and SAR development Outlook Looking ahead, the potential of induced proximity continues to grow. In a 2024 commentary, Dr. Stuart Schreiber, co-founder of the Broad Institute, highlighted molecular glues and bifunctional compounds as an innovative paradigm in drug discovery—capable of stabilizing, degrading, translocating, activating targets, as well as rewiring transcriptional circuits. For precision medicine, this may enable the long-sought goal of delivering “the right drug to the right patient at the right time—and in the right tissue.” Guided by its vision that “every drug can be made and every disease can be treated”, WuXi AppTec remains committed to leveraging its unique, fully integrated, end-to-end CRDMO model to help partners transform scientific innovation into transformative therapies for patients worldwide. 参考资料： [1] Arvinas Announces FDA Acceptance of the New Drug Application for Vepdegestrant for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer. Retrieved August 20, 2025, from https://www.globenewswire.com/news-release/2025/08/08/3130368/0/en/Arvinas-Announces-FDA-Acceptance-of-the-New-Drug-Application-for-Vepdegestrant-for-the-Treatment-of-ESR1m-ER-HER2-Advanced-Breast-Cancer.html [2] C4 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights. Retrieved August 20, 2025, from https://ir.c4therapeutics.com/news-releases/news-release-details/c4-therapeutics-reports-second-quarter-2025-financial-results [3] Monte Rosa Announces Publication in Science of Key Insights that Enable Next Generation Molecular Glue Degrader Medicines. Retrieved August 20, 2025, from https://ir.monterosatx.com/news-releases/news-release-details/monte-rosa-announces-publication-science-key-insights-enable [4] Monte Rosa Therapeutics Announces First Subjects Dosed in Phase 1 Study of MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory Diseases. Retrieved August 20, 2025, from https://ir.monterosatx.com/news-releases/news-release-details/monte-rosa-therapeutics-announces-first-subjects-dosed-phase-1 [5] SEED Therapeutics Named Finalist for 2025 Prix Galien USA “Best Start-Up” Award. Retrieved August 20, 2025, from https://seedtherapeutics.com/seed-therapeutics-named-finalist-for-2025-prix-galien-usa-best-start-up-award/ [6] Revolution Medicines Announces FDA Breakthrough Therapy Designation for Elironrasib. Retrieved August 20, 2025, from https://ir.revmed.com/news-releases/news-release-details/revolution-medicines-announces-fda-breakthrough-therapy-0 [7] Revolution Medicines Announces Publication of a Peer-Reviewed Research Paper in Science on the Discovery and Development of Zoldonrasib, a RAS(ON) G12D-Selective Inhibitor. Retrieved August 20, 2025, from https://ir.revmed.com/news-releases/news-release-details/revolution-medicines-announces-publication-peer-reviewed [8] VantAI and Halda Therapeutics Forge Alliance to Discover Next-Generation RIPTAC Medicines. Retrieved August 20, 2025, from https://haldatx.com/vantai-and-halda-therapeutics-forge-alliance-to-discover-next-generation-riptac-medicines/ [9] Arvinas Reports Second Quarter 2025 Financial Results and Provides Corporate Update. Retrieved August 20, 2025, from https://ir.arvinas.com/news-releases/news-release-details/arvinas-reports-second-quarter-2025-financial-results-and [10] Targeted Protein Degrader. Retrieved August 20, 2025, from https://rcs.wuxiapptec.com/wp-content/uploads/RCS_Targeted-Protein-Degrader_20250818.pdf [11] Revolution Medicines and Iambic Announce Technology and Research Collaboration Using Iambic’s AI Discovery Tools to Pursue New Drug Candidates. Retrieved August 27, 2025, from https://ir.revmed.com/news-releases/news-release-details/revolution-medicines-and-iambic-announce-technology-and-research [12] Schreiber (2024). Molecular glues and bifunctional compounds: Therapeutic modalities based on induced proximity. Cell Chemical Biology, DOI: 10.1016/j.chembiol.2024.05.004 [13] Rapafusyn Pharmaceuticals Closes Over-Subscribed $44 Million Series A Financing to Advance Its Non-Degrading Molecular Glue Drug Discovery Platform. Retrieved September 11, 2025, from https://www.globenewswire.com/news-release/2025/09/04/3144896/0/en/Rapafusyn-Pharmaceuticals-Closes-Over-Subscribed-44-Million-Series-A-Financing-to-Advance-Its-Non-Degrading-Molecular-Glue-Drug-Discovery-Platform.html [14] Proxygen and EPFL Launch Strategic Collaboration to Advance AI-Driven Glue Discovery. Retrieved September 11, 2025, from https://www.globenewswire.com/news-release/2025/08/26/3139189/0/en/Proxygen-and-EPFL-Launch-Strategic-Collaboration-to-Advance-AI-Driven-Glue-Discovery.html [15] Molecular Glues Discovery: Challenges and Opportunities. Retrieved July 4, 2025 from https://wuxibiology.com/resource/discovery-of-molecular-glues-challenges-and-opportunities/ 免责声明：本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。 版权说明：欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。 分享，点赞，在看，聚焦全球生物医药健康创新